drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
Oral small-molecule tyrosine kinase inhibitor of ABL, PDGFR, and KIT; intended to suppress parallel/bypass RTK and tumor–stroma signaling.
nci_thesaurus_concept_id
C62035
nci_thesaurus_preferred_term
Imatinib
nci_thesaurus_definition
An antineoplastic agent that inhibits the Bcr-Abl fusion protein tyrosine kinase, an abnormal enzyme produced by chronic myeloid leukemia cells that contain the Philadelphia chromosome. Imatinib also inhibits the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF)/c-kit; the SCF/c-kit receptor tyrosine kinase is activated in gastrointestinal stromal tumor (GIST). This agent inhibits proliferation and induces apoptosis in cells that overexpress these oncoproteins.
drug_mesh_term
Imatinib Mesylate
drug_category
SMALL MOLECULE DRUG
drug_class
Inhibitor
drug_delivery_route
Oral
drug_mechanism_of_action
ATP-competitive tyrosine kinase inhibitor of ABL (including BCR-ABL), PDGFR, and KIT; prevents kinase autophosphorylation and downstream MAPK and PI3K/AKT signaling, inhibiting proliferation and inducing apoptosis in oncogene-driven cells and suppressing PDGF-mediated tumor–stroma signaling.
drug_name
Imatinib
nct_id_drug_ref
NCT05816785